<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2903233440
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DETRUSITOL 2 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOLTERODINE TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            VIATRIS PHARMA S.R.L.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Detrusitol is tolterodine. Tolterodine belongs to a class of medicinal products called antimuscarinics.</p><p><s>&nbsp;</s></p><p>Detrusitol is used for the treatment of the symptoms of overactive bladder syndrome. If you have overactive bladder syndrome, you may find that:</p><ul><li>you are unable to control urination,</li></ul><ul><li>you need to rush to the toilet frequently with no advance warning.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Detrusitol</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to tolterodine or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have difficulty passing urine from the bladder (urinary retention)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an uncontrolled narrow-angle glaucoma (high pressure in the eyes with loss of eyesight that is not being adequately treated)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from myasthenia gravis (excessive weakness of the muscles)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from severe ulcerative colitis (ulceration and inflammation of the colon)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from a toxic megacolon (acute dilatation of the colon)</p><p>&nbsp;</p><p><strong>Warnings and Precautions</strong></p><p>Talk to your doctor or pharmacist before starting your treatment with Detrusitol if you think any of these might apply to you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have difficulties in passing urine and/or a poor stream of urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a gastro-intestinal disease that affects the passage and/or digestion of food</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from kidney problems (renal insufficiency)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a liver condition<s> </s></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from neuronal disorders that affect your blood pressure, bowel or sexual function (any neuropathy of the autonomic nervous system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a hiatal hernia (herniation of an abdominal organ)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from decreased bowel movements or suffer from severe constipation (decreased gastrointestinal motility)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a heart condition such as:</p><p>o&nbsp;&nbsp; An abnormal heart tracing (ECG)</p><p>o&nbsp;&nbsp; A slow heart rate (bradycardia)</p><p>o&nbsp;&nbsp; Relevant pre-existing cardiac diseases such as:</p><p>- cardiomyopathy (weak heart muscle)</p><p>- myocardial ischaemia (reduced blood flow to the heart)</p><p>- arrhythmia (irregular heartbeat)</p><p>- heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have abnormally low levels of potassium (hypokalaemia), calcium (hypocalcaemia) or magnesium (hypomagnesaemia) in your blood.</p><p>&nbsp;</p><p><strong>Other medicines and Detrusitol</strong></p><p>Tell your doctor if you are taking or have recently taken other medicines including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Tolterodine, the active substance of Detrusitol, may interact with other medicinal products.</p><p>&nbsp;</p><p>It is not recommended to use tolterodine in combination with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (containing e.g. erythromycin, clarithromycin);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for the treatment of fungal infections (containing e.g. ketoconazole, itraconazole);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for the treatment of HIV.</p><p>&nbsp;</p><p>Detrusitol should be used with caution when taken in combination with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect the passage of food (containing e.g. metoclopramide and cisapride)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the treatment of irregular heartbeat (containing e.g. amiodarone, sotalol, quinidine, procainamide)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines with a similar mode of action to Detrusitol (antimuscarinic properties) or medicines with an opposite mode of action to Detrusitol (cholinergic properties). Ask your doctor if you are unsure.</p><p>&nbsp;</p><p><strong>Detrusitol with food and drink</strong></p><p>Detrusitol can be taken before, after or during a meal.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><strong>Pregnancy </strong></p><p>You should not take Detrusitol when you are pregnant. Tell your doctor immediately if you are pregnant, think you may be pregnant or are planning to have a baby.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>No data concerning the excretion of tolterodine into breast milk are available. Breast-feeding is not recommended during administration of Detrusitol.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Detrusitol may make you feel dizzy, tired or affect your sight; your ability to drive or operate machinery may be affected.</p><p>&nbsp;</p><p><strong>Detrusitol contains sodium</strong></p><p>Detrusitol contains less than 1 mmol sodium (23 mg) per 2 mg film-coated tablets, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage</strong></p><p>Always take Detrusitol exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The usual dose is one 2 mg tablet twice per day, except for patients who have a kidney or a liver condition or who report side effects, for whom the doctor may reduce the dose to one 1&nbsp;mg tablet twice per day.</p><p>&nbsp;</p><p>Detrusitol is not recommended for children.</p><p>&nbsp;</p><p>The tablets are for oral use and should be swallowed whole.</p><p>&nbsp;</p><p><strong>Duration of treatment</strong></p><p>Your doctor will tell you how long you should use Detrusitol. Do not stop treatment early because you do not see an immediate effect. Your bladder will need some time to adapt. Finish the course of tablets prescribed by your doctor. If you have not noticed any effect by then, talk to your doctor.</p><p>&nbsp;</p><p>The benefit of the treatment should be re-evaluated after 2 or 3 months.</p><p>&nbsp;</p><p><strong>Always consult your doctor if you are thinking of stopping the treatment. </strong></p><p>&nbsp;</p><p><strong>If you take more Detrusitol than you should:</strong></p><p>If you or somebody else takes too many tablets, contact your doctor or pharmacist immediately.</p><p>&nbsp;</p><p><strong>If you forget to take Detrusitol</strong></p><p>If you forget to take a dose at the usual time, take it as soon as you remember, unless it is almost time for your next dose. In that case, omit the forgotten dose and follow the normal dose schedule.</p><p>Do not take a double dose to make up for a forgotten one.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>You should see your doctor immediately or go to the A&amp;E department if you experience symptoms of angioedema, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen face, tongue or pharynx</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty to swallow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives and difficulty in breathing</p><p>&nbsp;</p><p>You should also seek medical attention if you experience a hypersensitivity reaction (for example itching, rash, hives, difficulty breathing). This occurs uncommonly (occurs in less than 1 in 100 patients).</p><p>&nbsp;</p><p>Tell your doctor immediately or go to the casualty department if you notice any of the following:</p><ul><li>chest pain, difficulty breathing or getting tired easily (even at rest), difficulty breathing at night, swelling of the legs.</li></ul><p>These may be symptoms of heart failure. This occurs uncommonly (occurs in less than 1 in 100 patients).</p><p>&nbsp;</p><p>The following side effects have been observed during treatment with Detrusitol with the following frequency:</p><p>&nbsp;</p><p><strong>Very common: </strong>may affect more than<strong> </strong>1 in 10 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in 10 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, sleepiness, sensation of pins and needles in the fingers and toes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry eyes, blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty with digestion (dyspepsia), constipation, abdominal pain, excessive amounts of air or gases in the stomach or the intestine, vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful or difficult urination, inability to empty the bladder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, chest pain, extra fluid in the body causing swelling (e.g. in the ankles)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased weight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&nbsp;</p><p><strong>Uncommon:</strong> may affect up to 1 in 100 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervousness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased heart rate, heart failure, irregular heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Memory impairment</p><p><u>&nbsp;</u></p><p>Additional reactions reported include severe allergic reactions, confusion, hallucinations, flushed skin, angioedema, and disorientation. There have also been reports of worsening symptoms of dementia in patients being treated for dementia.</p><p>&nbsp;</p><p>If any side effects become worse, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting</strong><strong> of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><ul><li><strong>Saudi Arabia</strong></li></ul><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: &nbsp;https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p><ul><li><strong>&nbsp;</strong><strong>Other</strong><strong> GCC States</strong></li></ul><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. &nbsp;</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>&nbsp;Store below 25&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tolterodine.</p><p>Each Detrusitol 2 mg tablet contains 2 mg of tolterodine tartrate, equivalent to 1.37 mg of tolterodine</p><p>&nbsp;</p><p>The other ingredients are:</p><p>Core: Microcrystalline cellulose, calcium hydrogen phosphate dihydrate, sodium starch glycolate (Type B) (see section 2 &ldquo;Detrusitol contains sodium&rdquo;), magnesium stearate and colloidal anhydrous silica.</p><p>&nbsp;</p><p>Film coating: Hypromellose, microcrystalline cellulose, stearic acid and titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Detrusitol 2 mg tablets are white, round, biconvex tablets engraved with arcs above and below the letters “DT”.

Detrusitol 2 mg tablets are available in the following pack sizes:
Blister packs containing:
-	28 tablets (2 x 14)

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Viatris Pharma S.r.l.</p><p>Via Vittor Pisani 20, Milano, CAP 20124- Italy</p><p>&nbsp;</p><p><u>Manufacturer</u></p><p>Pfizer Italia S.r.l., Localit&agrave; Marino del Tronto, 63100 Ascoli Piceno</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في ديتروسيتول هو تولتيرودين. ينتمي تولتيرودين إلى فئة المنتجات الدوائية المسماة مضادات المُسكارين.</p><p dir="RTL">يستخدم ديتروسيتول لعلاج أعراض متلازمة فرط نشاط المثانة. إذا كنت تعاني من متلازمة فرط نشاط المثانة، فقد تُلاحظ التالي:</p><ul><li dir="RTL">أنك غير قادر على التحكم في التبول،</li><li dir="RTL">أنك بحاجة إلى الذهاب بسرعة إلى المرحاض باستمرار ودون إنذار مسبق.</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ديتروسيتول</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية (فرط التحسس) تجاه تولتيرودين أو أي من المكونات الأخرى لهذا الدواء. (المدرجة في القسم ٦)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صعوبة في إخراج البول من المثانة (احتباس البول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من زرق ضيق الزاوية غير متحكم به (ضغط عالٍ في العينين مع فقد الرؤية لا يُعالج بصورة ملائمة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وهن عضلي وَبيل (ضعف مفرط في العضلات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب القولون التقرحي الشديد (تقرح والتهاب القولون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضخم القولون السمي (توسع حاد في القولون)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ديتروسيتول</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل البدء في علاجك بديتروسيتول إذا كنت تعتقد أن أي من التالي قد ينطبق عليك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صعوبة في إخراج البول و/أو ضعف في تدفق البول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض معدي معوي يؤثر على مرور و/أو هضم الطعام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى (القصور الكلوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة ما بالكبد<s> </s></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات بالخلايا العصبية تؤثر على ضغط دمك أو الأمعاء أو الوظيفة الجنسية (أي اعتلال بالأعصاب في الجهاز العصبي المستقل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بفتق حجابي (انفتاق في عضو بالبطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض معدل التبرز أو من إمساك شديد (انخفاض الحركة المعدية المعوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة قلبية مثل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال مخطط ﺿﺮﺑﺎﺕ ﺍﻟﻘﻠﺐ (رسم القلب)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء معدل نبضات القلب (تباطؤ القلب)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض قلبية ذات صلة، وموجودة بالفعل مثل:</p><p dir="RTL">- اعتلال عضلة القلب (ضعف عضلة القلب)</p><p dir="RTL">- إقفار عضلة القلب (انخفاض تدفق الدم إلى القلب)</p><p dir="RTL">- عدم انتظام ضربات القلب (ضربات قلب غير منتظمة)</p><p dir="RTL">- فشل القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مستويات منخفضة بشكل غير طبيعي من البوتاسيوم (نقص بوتاسيوم الدم) أو الكالسيوم (نقص كالسيوم الدم) أو المغنيسيوم (نقص مغنيسيوم الدم) في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخرًا أدوية أخرى بما في ذلك الأدوية التي لا تتطلب وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتفاعل تولتيرودين، المادة الفعالة في ديتروسيتول، مع منتجات دوائية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُنصح باستخدام تولتيرودين بالتزامن مع:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية (التي تحتوي مثلًا على إريثروميسين، كلاريثروميسين)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوى الفطرية (التي تحتوي مثلًا على كيتوكونازول، إيتراكونازول)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية (HIV).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام ديتروسيتول بحذر عند تناوله بالتزامن مع:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على مسار الطعام (التي تحتوي مثلًا على ميتوكلوبراميد وسيسابريد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعالج عدم انتظام ضربات القلب (التي تحتوي مثلًا على أميودارون، سوتالول، كينيدين، بروكايناميد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لها طريقة عمل مشابهة لديتروسيتول (ذات خصائص مضادة للمُسكارين) أو الأدوية التي لها طريقة عمل مخالفة لديتروسيتول (ذات خصائص كولينية). استشر طبيبك، إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول ديتروسيتول مع الطعام والشراب</strong></p><p dir="RTL">يُمكن تناول ديتروسيتول قبل الوجبة أو بعدها أو خلالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong> <strong>والرضاعة</strong></p><p dir="RTL"><strong>الحمل </strong></p><p dir="RTL">ينبغي عدم تناول ديتروسيتول أثناء الحمل. يجب إخبار الطبيب على الفور في حالة الحمل أو إذا كنت تعتقدين أنك ربما تكونين حاملًا أو تخططين لإنجاب طفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">لا توجد بيانات متاحة بخصوص إفراز تولتيرودين في لبن الأم. لا يُنصح بالرضاعة الطبيعية أثناء تلقي ديتروسيتول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير ديتروسيتول على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك ديتروسيتول تشعر بالدوار أو الإرهاق أو قد يؤثر على بصرك؛ قد تتأثر قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات</strong> <strong>هامة</strong> <strong>حول</strong> <strong>بعض</strong> <strong>مكونات</strong> <strong>ديتروسيتول</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>ديتروسيتول على الصوديوم</strong></p><p dir="RTL">يحتوي ديتروسيتول<strong> </strong>على أقل من ١ ملليمول من الصوديوم (٢٣ ملجم) لكل قرص مغلف بطبقة رقيقة تركيزه ٢ ملجم، وهذا يعني أنه يُعد أساسًا &quot;خاليًا من الصوديوم&quot;.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة</strong></p><p dir="RTL">احرص دومًا على تناول ديتروسيتول تمامًا كما أخبرك طبيبك. ينبغي لك استشارة طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة هي قرص ٢ ملجم واحد مرتين يوميًا، باستثناء حالات المرضى الذين يعانون من حالات صحية في الكلية أو الكبد، أو الذين يبلغون عن آثار جانبية، حيث قد يقوم الطبيب بخفض جرعاتهم إلى قرص ١ ملجم واحد مرتين يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُوصى باستخدام ديتروسيتول مع الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص مخصصة للاستخدام عبر الفم وينبغي ابتلاعها كاملة.</p><p dir="RTL">&nbsp;</p><p><strong>مدة العلاج</strong></p><p dir="RTL">سيخبرك طبيبك عن المدة التي ينبغي عليك استخدام ديتروسيتول خلالها. لا توقف العلاج مبكرًا إذا لم تلاحظ تأثيرًا فوريًا. ستحتاج المثانة بعض الوقت لكي تتكيف مع العلاج. أكمل دورة العلاج بالأقراص التي وصفها طبيبك. إذا لم تلاحظ أي تأثير، فتحدث في الأمر مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تنبغي إعادة تقييم فائدة العلاج بعد شهرين أو ٣ أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشر طبيبك دائمًا إذا كنت تفكر في إيقاف العلاج. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من ديتروسيتول</strong></p><p dir="RTL">إذا تناولت أنت أو شخص آخر كمية من الأٌقراص أكبر مما ينبغي، فاتصل بطبيبك أو الصيدلي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة ديتروسيتول</strong></p><p dir="RTL">إذا نسيت تناول إحدى الجرعات في الموعد المعتاد، فتناولها في أقرب وقت ممكن بعدما تتذكر، ما لم يحن ميعاد الجرعة التي تليها. في تلك الحالة، تجاهل الجرعة التي نسيت تناولها وتابع جدول الجرعات الطبيعي.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك زيارة طبيبك على الفور أو الذهاب إلى قسم الحوادث والطوارئ إذا واجهت أعراض تورم وعائي مثل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو اللسان أو البلعوم</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى وصعوبة في التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL">كذلك ينبغي عليك اللجوء إلى الرعاية الطبية إذا تعرضت لتفاعل فرط تحسس (مثل، الحكة والطفح الجلدي والشرى وصعوبة التنفس). يحدث التفاعل بشكل غير شائع (قد يصيب أقل من ١ من كل <strong>١٠٠ </strong>مريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور أو اذهب إلى قسم الحوادث إذا لاحظت ظهور أي مما يلي:</p><ul><li dir="RTL">ألم الصدر أو صعوبة في التنفس أو الإحساس بالتعب بسهولة (حتى أثناء الراحة) أو صعوبة في التنفس أثناء الليل أو تورم الساقين.</li></ul><p dir="RTL">فقد تكون هذه أعراضًا لفشل القلب. يحدث هذا التفاعل بشكل غير شائع (قد يصيب أقل من ١ من كل <strong>١٠٠</strong> مريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظت الآثار الجانبية التالية أثناء العلاج بديتروسيتول، بالمعدلات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا:</strong> قد تصيب أكثر من ١ من كل <strong>١٠</strong> أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong> قد تصيب ما يصل إلى ١ من كل <strong>١٠</strong> أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الشعبي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، النعاس، الشعور بالشكشكة والوخز في أصابع اليدين والقدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين وتغيم الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الهضم (عسر الهضم)، الإمساك، ألم البطن، كميات كبيرة من الهواء أو الغازات في المعدة أو الأمعاء، القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم أثناء التبول أو صعوبة التبول، عدم القدرة على إفراغ المثانة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب، ألم الصدر، وجود سوائل زائدة داخل الجسم مسببة التورم (في الكاحلين مثلًا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوزن الزائد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة:</strong> قد تصيب ما يصل إلى ١ من كل <strong>١٠٠</strong> شخص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العصبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل نبضات القلب، فشل القلب، عدم انتظام ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الذاكرة</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">تتضمن التفاعلات الإضافية المبلغ عنها تفاعلات الحساسية الشديدة والتشوش والهلاوس واحمرار الجلد والتورم الوعائي والتوهان. كما كانت هناك بلاغات عن تفاقم لأعراض الخرف في المرضى الذين يتلقون علاجًا للخرف.</p><p dir="RTL">إذا تفاقمت أي من الأعراض الجانبية، أو لاحظت أي عرض جانبي غير مدرج في هذه النشرة، يُرجى إخبار طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><br />إذا ظهرت عليك أي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يشتمل هذا على أي آثار جانبية محتملة وغير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول مأمونية هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:131pt;margin-top:12.85pt;width:281.85pt;height:65.6pt;z-index:251657728;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormalCxSpFirst dir=RTL style='margin-bottom:12.0pt;mso-add-space:
    auto'><span lang=AR-SA dir=LTR>المركز الوطني للتيقظ الدوائي</span><span
    dir=RTL></span><span lang=AR-EG style='mso-bidi-language:AR-EG'><span
    dir=RTL></span>:<o:p></o:p></span></p>
    <ul style='margin-top:0in' type=circle>
     <li class=MsoNormalCxSpMiddle dir=RTL style='margin-bottom:12.0pt;
         mso-add-space:auto;mso-list:l5 level1 lfo6'><span lang=AR-SA>مركز
         الاتصال الموحد</span><span lang=AR-EG style='mso-bidi-language:AR-EG'>:
         </span><span lang=AR-SA>۱۹۹۹۹</span><span lang=AR-EG style='mso-bidi-language:
         AR-EG'><o:p></o:p></span></li>
     <li class=MsoNormalCxSpMiddle dir=RTL style='margin-bottom:12.0pt;
         mso-add-space:auto;mso-list:l5 level1 lfo6'><span lang=AR-SA dir=LTR>البريد
         </span><span lang=AR-SA>الإلكتروني</span><span lang=AR-EG
         style='mso-bidi-language:AR-EG'>: npc.drug@sfda.gov.sa<o:p></o:p></span></li>
     <li class=MsoNormalCxSpMiddle dir=RTL style='margin-bottom:12.0pt;
         mso-add-space:auto;mso-list:l5 level1 lfo6'><span lang=AR-SA dir=LTR>الموقع
         </span><span lang=AR-SA>الإلكتروني</span><span lang=AR-EG
         style='mso-bidi-language:AR-EG'>: https://ade.sfda.gov.sa<o:p></o:p></span></li>
    </ul>
    <p class=MsoNormalCxSpMiddle dir=RTL style='margin-top:0in;margin-right:
    .25in;margin-bottom:12.0pt;margin-left:0in;mso-add-space:auto;line-height:
    150%'><span lang=AR-EG style='mso-bidi-language:AR-EG'><span
    style='mso-spacerun:yes'> </span><o:p></o:p></span></p>
    <p class=MsoNormalCxSpLast dir=RTL style='margin-top:0in;margin-right:.25in;
    margin-bottom:12.0pt;margin-left:0in;mso-add-space:auto;line-height:150%'><span
    lang=AR-EG style='mso-bidi-language:AR-EG'><span
    style='mso-spacerun:yes'> </span><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><ul><li dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول الخليج الأخرى</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:130.9pt;margin-top:10.9pt;width:284.9pt;
 height:25.95pt;z-index:251658752;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL><span lang=AR-SA dir=LTR>الرجاء الاتصال
    بالمؤسسات والهيئات الوطنية في كل دولة</span><span dir=RTL></span><span
    lang=AR-EG style='mso-bidi-language:AR-EG'><span dir=RTL></span>.<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></tbody></table><p>&nbsp;يرجى الاتصال بالسلطة المختصة ذات الصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم<strong>&nbsp; </strong>ديتروسيتول بعد انتهاء فترة الصلاحية المُبينة على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يحفظ تحت ٢٥ درجة مئوية.</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تولتيرودين.</p><p dir="RTL">يحتوي كل قرص من ديتروسيتول ١ ملجم على ١ ملجم من طرطرات تولتيرودين، بما يعادل ٠,٦٨ ملجم من تولتيرودين</p><p dir="RTL">يحتوي كل قرص من ديتروسيتول ٢ ملجم على ٢ ملجم من طرطرات تولتيرودين، بما يعادل ١,٣٧ ملجم من تولتيرودين</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><strong>قلب القرص: </strong>سليولوز بلوري مكروي وفوسفات هيدروجين الكالسيوم ثنائي الهيدرات وجليكولات نشا الصوديوم (النوع B) (انظر القسم ٢ &quot;يحتوي ديتروسيتول على الصوديوم&quot;) وستيارات المغنيسيوم وسيليكا غروانية لا مائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الغلاف الرقيق: </strong>هيبروميلوز وسليولوز بلوري مكروي وحمض الستياريك وثاني أكسيد التيتانيوم (E171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ديتروسيتول ٢ ملجم هي أقراص بيضاء دائرية مُحدبة الوجهين، تحمل أقواسا محفورة أعلى وأسفل الأحرف &quot;DT&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوافر أقراص ديتروسيتول ٢ ملجم في أحجام العبوات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">عبوات شرائط بليستر تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٢٨ قرصًا (٢ &times; ٤<strong>١</strong>)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم طرح جميع أحجام العبوات في الأسواق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك رخصة التسويق</p><p>Viatris Pharma S.r.l.</p><p>Via Vittor Pisani 20, Milano, CAP 20124- Italy, إيطاليا</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المصنع</u></p><p>Pfizer Italia S.r.l., Via del Commercio 25&ndash;27, 63046 Marino del Tronto (AP)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DETRUSITOL 2 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains tolterodine tartrate 2 mg corresponding to 1.37 mg of tolterodine.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

The film-coated tablets are white, round and biconvex. The 2 mg tablet is engraved with arcs above and below the letters DT.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urge incontinence and/or of increased urinary frequency and urgency in patients with overactive bladder syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Adults (including elderly patients):</em></strong></p><p>The recommended dose is 2 mg twice daily, except in patients with impaired liver function or severely impaired renal function [GFR (inulin clearance) <u>&lt;</u> 30 mL/min] for whom the recommended dose is 1&nbsp;mg twice daily (see section 4.4). In case of troublesome side effects, the dose may be reduced from 2&nbsp;mg to 1 mg twice daily.</p><p>&nbsp;</p><p>The effect of treatment should be re-evaluated after 2 to 3 months (see section 5.1).<strong> </strong></p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The efficacy of Detrusitol has not been demonstrated in children (see section 5.1). Therefore, Detrusitol is not recommended for children.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tolterodine is contraindicated in patients with
- Urinary retention
- Uncontrolled narrow-angle glaucoma
- Myasthenia gravis
- Known hypersensitivity to tolterodine or excipients (see section 6)
- Severe ulcerative colitis 
- Toxic megacolon

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tolterodine shall be used with caution in patients with</p><p>- Significant bladder outlet obstruction at risk of urinary retention</p><p>- Gastrointestinal obstructive disorders, e.g. pyloric stenosis</p><p>- Renal impairment (see section 4.2)</p><p>- Hepatic disease (see sections 4.2 and 5.2)</p><p>- Autonomic neuropathy</p><p>- Hiatus hernia</p><p>- Risk for decreased gastrointestinal motility</p><p>&nbsp;</p><p>Multiple total daily doses of immediate-release 4 mg (therapeutic) and 8 mg (supratherapeutic) tolterodine have been shown to prolong the QTc interval (see section 5.1). The clinical relevance of these findings is unclear and will depend on individual patient risk factors and susceptibilities present. Tolterodine should be used with caution in patients with risk factors for QT prolongation, including:</p><p>- Congenital or documented acquired QT prolongation</p><p>- Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia</p><p>- Bradycardia</p><p>- Relevant pre-existing coronary heart diseases (cardiomyopathy, myocardial ischaemia, arrhythmia, cardiac decompensation)</p><p>- Concomitant administration of drugs known to prolong the QT interval, including Class 1A (e.g. quinidine, procainamide) and Class III (e.g. amiodarone, sotalol) anti-arrhythmics.</p><p>&nbsp;</p><p>In particular, tolterodine should be administered with caution when taking a potent CYP3A4 inhibitor (see section 5.1). Concomitant treatment with potent CYP3A4 inhibitors should be avoided (see section 4.5).</p><p>&nbsp;</p><p><u>Urinary retention</u></p><p>As with all treatments for symptoms of urinary urgency or urge incontinence, organic reasons for urge and frequency should be considered before treatment.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><u>Excipient information</u></p><p>Detrusitol 2 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per tablet.</p><p>Patients on low sodium diets can be informed that this medicinal product is essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant systemic medication with potent CYP3A4 inhibitors such as macrolide antibiotics (erythromycin and clarithromycin), antifungal agents (ketoconazole and itraconazole) and antiproteases, is not recommended due to increased serum concentrations of tolterodine in poor CYP2D6 metabolisers with (subsequent) risk of overdosage (see section 4.4.).</p><p>&nbsp;</p><p>Concomitant medication with other drugs that possess antimuscarinic properties may result in more pronounced therapeutic effects and side effects. Conversely, the therapeutic effect of tolterodine may be reduced by concomitant administration of muscarinic cholinergic receptor agonists.</p><p>&nbsp;</p><p>The effect of prokinetics like metoclopramide and cisapride may be decreased by tolterodine<strong><em>.</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Concomitant treatment with fluoxetine, (a potent CYP2D6 inhibitor), does not result in a clinically significant interaction, since tolterodine and its CYP2D6-dependent metabolite, 5-hydroxymethyl tolterodine, are equipotent.</p><p>Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>A clinical study has indicated that tolterodine is not a metabolic inhibitor of CYP2D6, 2C19, 2C9, 3A4 or 1A2. Therefore, an increase of plasma levels of drugs metabolised by these isoenzymes is not expected when dosed in combination with tolterodine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of tolterodine in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Consequently, Detrusitol is not recommended during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>No data concerning the excretion of tolterodine into human milk are available. Tolterodine should be avoided during lactation.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As this drug may cause accommodation disturbances and influence reaction time, the ability to drive and use machines may be negatively affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Safety profile</u></p><p>Due to the pharmacological effect of tolterodine it may cause mild to moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and dry eyes.</p><p>&nbsp;</p><p>Table 1 below reflects the data obtained with Detrusitol in clinical trials and from post-marketing experience. The most commonly reported adverse reaction was dry mouth, which occurred in 35% of patients treated with Detrusitol tablets and in 10% of placebo treated patients. Headaches were also reported very commonly and occurred in 10.1% of patients treated with Detrusitol tablets and in 7.4% of placebo treated patients.</p><p>&nbsp;</p><p><u>Table of adverse reactions</u></p><p>The adverse reaction listed in the table below are presented by System Organ Class (SOC) and frequency categories, defined using the following convention: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness</p><p>&nbsp;</p><p><strong><u>Table 1: adverse reactions</u></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt;</strong><strong> </strong><strong>1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1,000 to </strong></p><p><strong>&lt;</strong><strong> </strong><strong>1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune System</p><p>Disorders&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity not&nbsp;</p><p>otherwise specified</p></td><td style="vertical-align:top"><p>Anaphylactoid reactions</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>Confusion, hallucinations, disorientation</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System</p><p>Disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness,</p><p>somnolence,</p><p>paresthesia</p></td><td style="vertical-align:top"><p>Memory impairment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry eyes,</p><p>abnormal vision including abnormal accommodation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Tachycardia,</p><p>cardiac failure, arrhythmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Dyspepsia,</p><p>constipation,</p><p>abdominal pain, flatulence,</p><p>vomiting,</p><p>diarrhoea</p></td><td style="vertical-align:top"><p>Gastroesophageal reflux</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry skin</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria,</p><p>urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue,</p><p>chest pain,</p><p>peripheral oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased weight</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Cases of aggravation of symptoms of dementia (e.g. confusion, disorientation, delusions) have been reported after tolterodine therapy was initiated in patients taking cholinesterase inhibitors for the treatment of dementia.</p><p><strong>&nbsp;</strong></p><p><u>Paediatric population</u></p><p>In two paediatric phase 3, randomised, placebo-controlled, double-blind studies conducted over 12&nbsp;weeks in 710 paediatric patients, the proportion of patients with urinary tract infections, diarrhoea and abnormal behaviour was higher in patients treated with tolterodine than in those treated with placebo (urinary tract infection: tolterodine 6.8 %, placebo 3.6 %; diarrhoea: tolterodine 3.3 %, placebo 0.9 %; abnormal behaviour: tolterodine 1.6 %, placebo 0.4 %) (see section 5.1).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements</u>.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><ul><li><strong>Saudi Arabia</strong></li></ul><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: &nbsp;https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p><ul><li><strong>&nbsp;</strong><strong>Other</strong><strong> GCC States</strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;Please contact the relevant competent authority.</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest dose given to healthy human volunteers of tolterodine tartrate is 12.8 mg as a single dose. The most severe adverse events observed were accommodation disturbances and micturition difficulties.</p><p>&nbsp;</p><p>In the event of tolterodine overdose, treat with gastric lavage and give activated charcoal.</p><p>Treat symptoms as follows:</p><p>* Severe central anticholinergic effects (e.g. hallucinations, severe excitation): treat with physostigmine.</p><p>* Convulsions or pronounced excitation: treat with benzodiazepines.</p><p>* Respiratory insufficiency: treat with artificial respiration.</p><p>* Tachycardia: treat with beta blockers.</p><p>* Urinary retention:&nbsp; treat with catheterisation.</p><p>* Mydriasis: treat with pilocarpine eye drops and/or place patient in dark room.</p><p>&nbsp;</p><p>An increase in QT interval was observed with a single daily dose of 8 mg immediate-release tolterodine (twice the recommended daily dose of standard formulation and equivalent to three times the peak exposure of the prolonged-release formulation) administered over 4 days. In the event of tolterodine overdose, standard supportive measures for managing QT prolongation should be adopted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: urinary antispasmodics, ATC Code: G04BD07&nbsp;</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Tolterodine is a competitive, specific muscarinic receptor antagonist with a selectivity for the urinary bladder over salivary glands <em>in vivo</em>.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>One of the tolterodine metabolites (5-hydroxymethyl derivative), exhibits a pharmacological profile similar to that of the parent compound. In extensive metabolisers, this metabolite contributes significantly to the therapeutic effect of tolterodine (see section 5.2).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Effect of the treatment can be expected within 4 weeks.</p><p>&nbsp;</p><p><em>Effects of treatment with Detrusitol 2 mg twice daily, after 4 and 12 weeks, respectively, compared with placebo (pooled data). Absolute change and percentage change relative to baseline</em></p><p>&nbsp;</p><p>_____________________________________________________________________________________________________</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Variable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | 4-week studies&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12-week studies</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; __________________________ |__________________________________________________________________________</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | Detrusitol Placebo&nbsp;&nbsp;&nbsp; &nbsp; Statistical Detrusitol&nbsp;&nbsp;&nbsp; Placebo&nbsp;&nbsp; Statistical</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | 2 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; significance vs.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significance vs.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | b.i.d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; b.i.d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; placebo</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; __________________________ |__________________________________________________________________________</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of micturitions &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | &ndash;1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ndash;0.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ndash;2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &ndash;1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per 24 hours&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | (-14%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-8%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-20%)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; (-12%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | n=392&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=189&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=354&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; n=176</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of incontinence&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | &ndash;1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ndash;1.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n.s.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ndash;1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &ndash;1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; episodes per&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | (-38%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-26%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (-47%)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; (-32%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 hours&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | n= 288&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=299&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; n=145</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean volume per&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | +25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; +10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ***</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; micturition (mL)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | (+17%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (+8%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (+22%)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; (+6%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | n=385&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=185&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=354&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; n=176</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of patients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | 16%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 15%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n.s.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with no or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | n=394&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=190&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n=356&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; n=177</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; minimal bladder problems&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;after treatment (%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ________________________________________________________________________________________________________</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n.s.=not significant; * = p <u>&lt;</u> 0.05; ** = p <u>&lt;</u> 0.01; *** = p <u>&lt;</u> 0.001</p><p>&nbsp;</p><p>&nbsp;</p><p>The effects of tolterodine were evaluated in patients, examined with urodynamic assessment at baseline and, depending on the urodynamic result, they were allocated to a urodynamic positive (motor urgency) or a urodynamic negative (sensory urgency) group. Within each group, the patients were randomised to receive either tolterodine or placebo. The study could not provide convincing evidence that tolterodine had effects over placebo in patients with sensory urgency.</p><p><strong><s>&nbsp;</s></strong></p><p>The clinical effects of tolterodine on QT interval are based on the ECGs obtained from over 600&nbsp;treated patients, including elderly patients and patients with pre-existing cardiovascular disease. The changes in QT interval did not significantly differ between placebo and active treatment groups.</p><p>The effect of tolterodine on QT prolongation was investigated further in 48 healthy male and female volunteers aged 18 to 55 years. Subjects were administered 2 mg BID and 4 mg BID tolterodine as the immediate-release formulations.&nbsp;&nbsp; The results (Fridericia corrected) at peak tolterodine concentration (1&nbsp;hour) showed mean QTc interval increases of 5.0 and 11.8 msec for tolterodine doses of 2 mg BID and 4 mg BID respectively and 19.3 msec for moxifloxacin (400 mg) which was used as the control drug. A pharmacokinetic/pharmacodynamic model has shown that QTc interval increases in poor metabolisers (devoid of CYP2D6) treated with tolterodine 2 mg BID are comparable to those observed in extensive metabolisers receiving 4 mg<em> </em>BID. At both doses of tolterodine, no subject, irrespective of their metabolic profile, exceeded 500 msec for absolute QTcF or 60 msec for change from baseline. These changes are considered particularly significant threshold values. The 4 mg BID dose corresponds to a peak exposure (Cmax) of three times that obtained with the highest therapeutic dose of Detrusitol prolonged release capsules.</p><p>&nbsp;</p><p><u>Paediatric population</u>Efficacy in the paediatric population has not been demonstrated. Two paediatric phase 3 randomised, placebo-controlled, double-blind 12-week studies were conducted using tolterodine prolonged-release capsules. A total of 710 paediatric patients (486 treated with tolterodine and 224 treated with placebo) aged 5 to 10 years with increased urinary frequency and urinary urgency were studied.</p><p>No significant difference between the two groups was observed in either study with regard to change from baseline in total number of incontinence episodes/week (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic characteristics specific for this formulation </u></p><p>Tolterodine is rapidly absorbed. Both tolterodine and the 5-hydroxymethyl metabolite reach maximal serum concentrations 1 to 3 hours after dose.</p><p>The half-life for tolterodine given as the tablet is 2 to 3 hours in extensive and about 10 hours in poor metabolisers (devoid of CYP2D6). Steady state concentrations are reached within 2 days after administration of the tablets.</p><p>Food does not influence the exposure to unbound tolterodine and the active 5-hydroxyethyl metabolite in extensive metabolisers, although the tolterodine levels increase when taken with food. Clinically relevant changes are likewise not expected in poor metabolisers.</p><p><u>Absorption</u></p><p>After oral administration, tolterodine is subject to CYP2D6 catalysed first-pass metabolism in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically equipotent metabolite.</p><p>The absolute bioavailability of tolterodine is 17% in extensive metabolisers and 65% in poor metabolisers (devoid of CYP2D6).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Tolterodine and the 5-hydroxymethyl metabolite bind primarily to orosomucoid.</p><p>The unbound fractions are 3.7% and 36%, respectively. The volume of distribution of tolterodine is 113 litres.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Tolterodine is extensively metabolised by the liver following oral dosing.</p><p>The primary metabolic route is mediated by the polymorphic enzyme CYP2D6 and leads to the formation of the 5-hydroxymethyl metabolite. Further metabolism leads to formation of the 5-carboxylic acid and N-dealkylated 5-carboxylic acid metabolites, which account for 51% and 29% of the metabolites recovered in the urine, respectively. A subset (about 7%) of the population is devoid of CYP2D6 activity. The identified pathway of metabolism for these individuals (poor metabolisers) is dealkylation via CYP3A4 to N-dealkylated tolterodine, which does not contribute to the clinical effect.</p><p>The remainder of the population consists of extensive metabolisers. The systemic clearance of tolterodine in extensive metabolisers is about 30 L/h. In poor metabolisers the reduced clearance leads to significantly higher serum concentrations of tolterodine (about 7-fold) and negligible concentrations of the 5-hydroxymethyl metabolite are observed.</p><p>&nbsp;</p><p>The 5-hydroxymethyl metabolite is pharmacologically active and equipotent with tolterodine.</p><p>Because of the differences in the protein-binding characteristics of tolterodine and the 5-hydroxymethyl metabolite, the exposure (AUC) of unbound tolterodine in poor metabolisers is similar to the combined exposure of unbound tolterodine and 5-hydroxymethyl derivative in patients with CYP2D6 activity given the same dosage regimen. The safety, tolerability and clinical response are similar, irrespective of phenotype.</p><p>&nbsp;</p><p>The excretion of radioactivity after administration of [<sup>14</sup>C]-tolterodine is about 77% in urine and 17% in faeces. Less than 1% of the dose is excreted as unchanged drug, and about 4% as the 5-hydroxymethyl metabolite. The carboxylated metabolite and the corresponding dealkylated metabolite account for about 51% and 29% of the urinary recovery, respectively.</p><p>&nbsp;</p><p>The pharmacokinetics is linear in the therapeutic dosage range.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>About 2-fold higher exposure of unbound tolterodine and its 5-hydroxymethyl metabolite is found in subjects with liver cirrhosis (see sections 4.2 and 4.4).</p><p>Impaired renal function: the mean exposure of unbound tolterodine and its 5-hydroxymethyl metabolite is doubled in patients with severe renal impairment [inulin clearance (GFR) <u>&lt; &nbsp;</u>30 mL/min].</p><p>The plasma levels of other metabolites were markedly increased (up to 12-fold) in these patients.</p><p>The clinical relevance of the increased exposure of these metabolites is unknown.</p><p>There is no data in mild to moderate renal impairment (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The exposure of the active substance per mg dose is similar in adults and adolescents. The mean exposure of the active substance per mg dose is approximately two-fold higher in children between</p><p>5 to 10 years than in adults (see sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In toxicity, mutagenicity, carcinogenicity and safety pharmacology studies, no clinically relevant effects have been observed, except those related to the pharmacological effects of the drug.</p><p>&nbsp;</p><p>Reproduction studies have been performed in mice and rabbits.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>In mice, there was no effect of tolterodine on fertility or reproductive function.</p><p>Tolterodine produced embryo death and foetal malformations at plasma exposures (Cmax or AUC) 20 or 7 times higher than those seen in treated humans.</p><p>In rabbits, no malformative effect was seen, but the studies were conducted at 20 or 3 times higher plasma exposure values (Cmax or AUC) than those expected in humans after therapeutic doses.</p><p>&nbsp;</p><p>Tolterodine, as well as its active human metabolites, prolong action potential duration (90% repolarisation) in canine Purkinje fibres (14-75 times therapeutic levels) and block K+ flow in hERG (cloned human ether-a-go-go-related gene) channels (0.5-26.1 times therapeutic levels).</p><p>&nbsp;</p><p>In studies conducted in dogs, prolongation of the QT interval has been observed after administration of tolterodine and its human active metabolites (3.1 to 61.0 times therapeutic levels).</p><p>The clinical relevance of this effect is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Core</u></p><p>Cellulose, microcrystalline</p><p>Calcium hydrogen phosphate dihydrate</p><p>Sodium starch glycolate (Type B)</p><p>Magnesium stearate</p><p>Colloidal anhydrous silica</p><p>&nbsp;</p><p><u>Film coating</u></p><p>Coating granules containing:</p><p>Hypromellose</p><p>Cellulose, microcrystalline</p><p>Stearic acid</p><p>Titanium dioxide E171</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Detrusitol after the expiry date which is stated on the carton / Blister after EXP:. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>Store below 25&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets are packed in either blisters made of PVC/PVDC and aluminium foil with a heat-seal coating of PVDC or HDPE bottles with LDPE closures or with PP Child Resistant Squeeze and Turn closures.</p><p>&nbsp;</p><p><u>Pack sizes </u></p><p>Detrusitol tablets are available in blister packs of 2x10, 3x10, 5x10 and 10x10 tablets, 1x14, 2x14 and 4x14 tablets, 280 and 560 tablets and in bottles of 60 and 500 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viatris Pharma S.r.l.
Via Vittor Pisani 20, Milano, CAP 20124- Italy

MANUFACUTRED BY
Pfizer Italia S.r.l., Località Marino del Tronto, 63100 Ascoli Piceno

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>